Cortexyme Announces $125 Million Private Placement

FLG Partner’s client, Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, announced February 5, 2020 that it has entered into stock purchase agreements with a group of institutional investors and an entity affiliated with a member…Read More

Read More
RAPT Therapeutics Completes IPO and

In December 2019, FLG client, RAPT Therapeutics announced earnings and results following the company’s initial public offering (IPO) which raised $33.8 million in net proceeds including the underwriters’ exercise of their over-allotment option to purchase additional shares at the IPO price. The Company’s stock commenced trading on the Nasdaq Global…Read More

Read More
Nitro Software Limited Completes IPO

December 11, 2019 – Nitro Software Limited (NTO) commenced trading on the Australian Securities Exchange (ASX) today, following a successful initial public offering raising total proceeds of $110.2 million at a price of $1.72 per share.  At the IPO listing price, Nitro has a market capitalization of $324.9 million and an…Read More

Read More
Oyster Point Pharma Completes Its IPO

December 5, 2019 – Oyster Point Pharma announced today the completion of its IPO. Company press release. FLG partner: Mark Murray.

Read More
Cutera, Inc. Engages FLG Partners

November 18, 2019 – Cutera, Inc. (NASDAQ: CUTR) announced today that it has engaged FLG Partners for CFO services. Company press release. FLG partner: Fuad Ahmad.

Read More